Sign Up to like & get recommendations! 0
Published in 2020 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-020-02318-x
Abstract: Patients with COVID-19 are known to be at risk of developing both venous, arterial and microvascular thrombosis, due to an excessive immuno-thrombogenic response to the SARS-CoV-2 infection. Overlapping syndromes of COVID-19 associated coagulopathy with consumptive… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Chest"
DOI: 10.1016/j.chest.2021.07.173
Abstract: TOPIC: Cardiovascular Disease TYPE: Medical Student/Resident Case Reports INTRODUCTION: COVID-19 (Coronavirus Disease of 2019) is a global pandemic caused by the rapidly spreading SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). Although COVID-19 primarily affects the respiratory… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Thrombosis and Haemostasis"
DOI: 10.1055/s-0042-1758653
Abstract: Long-term anticoagulation is used worldwide to prevent or treat thrombotic events. Anticoagulant therapy using vitamin K antagonists (VKAs) is well established; however, anticoagulants carry an increased risk of potentially life-threatening bleeding. In cases of bleeding… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "International Journal of Laboratory Hematology"
DOI: 10.1111/ijlh.13876
Abstract: COVID‐19 associated coagulopathy (CAC) can either be localized or systemic hypercoagulable state with increased risk of thromboembolism. This study looked into the usefulness of Thromboelastography (TEG) and the velocity curve (V‐curve) derivative from TEG in… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Transfusion"
DOI: 10.1111/trf.15169
Abstract: Traumatic brain injury (TBI)‐induced coagulopathy has long been recognized as a significant risk for poor outcomes in patients with TBI, but its pathogenesis remains poorly understood. As a result, current treatment options for the condition… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Blood"
DOI: 10.1182/blood.2020006000
Abstract: Abstract Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings consistent with infection-induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Blood"
DOI: 10.1182/blood.2022015917
Abstract: Coronavirus-associated coagulopathy (CAC) is a morbid and lethal sequela of SARS-CoV-2 infection. CAC results from a perturbed balance between coagulation and fibrinolysis and occurs in conjunction with exaggerated activation of monocytes/macrophages (MO/Mφs) and the mechanisms… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Journal of Neuroinflammation"
DOI: 10.1186/s12974-021-02192-1
Abstract: Traumatic brain injury (TBI) remains one of the leading causes of death and disability worldwide; more than 10 million people are hospitalized for TBI every year around the globe. While the primary injury remains unavoidable… read more here.
Sign Up to like & get recommendations! 2
Published in 2022 at "Current pharmaceutical biotechnology"
DOI: 10.2174/1389201023666220527110455
Abstract: Recent reports show coagulopathy as a potential complication and poorer outcome of coronavirus disease 2019 (COVID-19), especially in those with comorbid conditions such as diabetes and hypertension as thrombosis could result in stroke and heart… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Life"
DOI: 10.3390/life11101032
Abstract: Background: COVID-19-associated coagulopathy (CAC) exacerbates the course of coronavirus infection and contributes to increased mortality. Current recommendations for CAC treatment include the use of low-molecular weight heparins (LMWH) at prophylactic or therapeutic doses, as well… read more here.